Search Results for: Inhibitors

October 13, 2024October 13, 2024

Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events.

Melanoma Literature

Publication date: Oct 12, 2024 Given the broad implementation of immune checkpoint inhibitors (ICI) for cancer therapy, we encounter a variety of immune-related adverse events (irAE) including immune-related blood eosinophilia. ... Read more

October 13, 2024October 13, 2024

Design of inhibitors of SARS-CoV-2 papain-like protease deriving from GRL0617: Structure-activity relationships.

Coronavirus Literature

Publication date: Nov 01, 2024 The unique and complex structure of papain-like protease (PL) of the SARS-CoV-2 virus represents a difficult challenge for antiviral development, yet it offers a compelling ... Read more

October 13, 2024October 13, 2024

Integrating computational and experimental approaches in discovery and validation of MmpL3 pore domain inhibitors for specific labelling of Mycobacterium tuberculosis.

Tuberculosis Literature

Publication date: Nov 01, 2024 Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), continues to pose a significant global health threat. Identifying new druggable targets is crucial for the advancement of ... Read more

October 12, 2024October 12, 2024

Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel.

Melanoma Literature

Publication date: Oct 10, 2024 Combined immunotherapy (ipilimumab + nivolumab) has improved survival in stage IV melanoma patients, making Health-related Quality of Life (HrQoL) crucial due to potential immune-related adverse events (irAEs). ... Read more

October 12, 2024October 12, 2024

Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel.

Melanoma Literature

October 12, 2024October 12, 2024

Molecular Mechanism-Driven Discovery of Novel Small Molecule Inhibitors against Drug-Resistant SARS-CoV-2 M Variants.

Coronavirus Literature

Publication date: Oct 10, 2024 Under the selective pressure of nirmatrelvir, a peptidomimetic covalent drug targeting SARS-CoV-2 M, various drug-resistant mutations on M have been acquired in vitro. Among the ... Read more

October 11, 2024October 11, 2024

Molecular Mechanism-Driven Discovery of Novel Small Molecule Inhibitors against Drug-Resistant SARS-CoV-2 M Variants.

Coronavirus Literature

October 11, 2024October 11, 2024

Deep convolutional neural network-based identification and biological evaluation of MAO-B inhibitors.

Parkinson's Disease Literature

Publication date: Oct 08, 2024 Parkinson’s disease (PD) is one of the most prominent motor disorder of adult-onset dementia connected to memory and other cognitive abilities. Individuals with this vicious ... Read more

October 9, 2024October 9, 2024

Effects of SARS-CoV-2 Main Protease Mutations at Positions L50, E166, and L167 Rendering Resistance to Covalent and Noncovalent Inhibitors.

Coronavirus Literature

Publication date: Oct 07, 2024 SARS-CoV-2 propagation under nirmatrelvir and ensitrelvir pressure selects for main protease (MPro) drug-resistant mutations E166V (DRM2), L50F/E166V (DRM3), E166A/L167F (DRM4), and L50F/E166A/L167F (DRM5). DRM2-DRM5 undergoes ... Read more

October 9, 2024October 9, 2024

Effects of SARS-CoV-2 Main Protease Mutations at Positions L50, E166, and L167 Rendering Resistance to Covalent and Noncovalent Inhibitors.

Coronavirus Literature